Vectura logo

VEC - Vectura Share Price

97.8p -1.1  -1.1%

Last Trade - 10/07/20

Mid Cap
Market Cap £595.4m
Enterprise Value £528.9m
Revenue £178.3m
Position in Universe 478th / 1816
Unlock VEC Revenue
Relative Strength (%)
1m +6.91%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.57%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
58.0 72.0 126.5 148 160.5 178.3 168.2 176 +25.2%
+131.3 +76.5
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Vectura Group PLC revenues increased 11% to £178.3M. Net loss decreased 75% to £22.1M. Revenues reflect Japan segment increase of 54% to £54.1M, United Kingdom segment increase of 16% to £64.3M. Lower net loss reflects Impairment of Intangibles Excl Goodwill decrease of 80% to £8.2M (expense), Research and development expenses decrease of 10% to £50.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for VEC
Graphical History


VEC Revenue Unlock VEC Revenue

Net Income

VEC Net Income Unlock VEC Revenue

Normalised EPS

VEC Normalised EPS Unlock VEC Revenue

PE Ratio Range

VEC PE Ratio Range Unlock VEC Revenue

Dividend Yield Range

VEC Dividend Yield Range Unlock VEC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VEC EPS Forecasts Unlock VEC Revenue
Profile Summary

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated August 13, 1997
Public Since July 2, 2004
No. of Shareholders: n/a
No. of Employees: 480
Sector Healthcare
Industry Pharmaceuticals
Index FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSE Smallcap , FTSE Smallcap Ex Its , FTSE Techmark Focus , FTSE Techmark All Share , ,
Exchange London Stock Exchange (Full)
Shares in Issue 602,022,863
Free Float (0.0%)
Eligible for
VEC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VEC
Upcoming Events for VEC
Frequently Asked Questions for Vectura
What is the Vectura share price?

As of 10/07/20, shares in Vectura are trading at 97.8p, giving the company a market capitalisation of £595.4m. This share price information is delayed by 15 minutes.

How has the Vectura share price performed this year?

Shares in Vectura are currently trading at 97.8p and the price has moved by 21.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vectura price has moved by 45.71% over the past year.

What are the analyst and broker recommendations for Vectura?

Of the analysts with advisory recommendations for Vectura, there are there are currently 5 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vectura is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Vectura next release its financial results?

Vectura is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Vectura dividend yield?

Vectura does not currently pay a dividend.

Does Vectura pay a dividend?

Vectura does not currently pay a dividend.

When does Vectura next pay dividends?

Vectura does not currently pay a dividend.

How do I buy Vectura shares?

To buy shares in Vectura you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vectura?

Shares in Vectura are currently trading at 97.8p, giving the company a market capitalisation of £595.4m.

Where are Vectura shares listed? Where are Vectura shares listed?

Here are the trading details for Vectura:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: VEC
What kind of share is Vectura?

Based on an overall assessment of its quality, value and momentum, Vectura is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vectura share price forecast 2020?

Shares in Vectura are currently priced at 97.8p. At that level they are trading at 24.87% discount to the analyst consensus target price of 130.17.

Analysts covering Vectura currently have a consensus Earnings Per Share (EPS) forecast of 0.05547 for the next financial year.

How can I tell whether the Vectura share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vectura. Over the past six months, the relative strength of its shares against the market has been 21.66%. At the current price of 97.8p, shares in Vectura are trading at 10.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vectura PE Ratio?

We were not able to find PE ratio data for Vectura.

Who are the key directors of Vectura?

Vectura's management team is headed by:

Neil Warner - NID
Bruno Angelici - NEC
Per-Olof Andersson - NID
Joanne Hombal - EVP
John Murphy - GCN
Geraldine Venthoye - EVP
David Lescuyer - EVP
Paul Fry - CFO
Kevin Matthews - NID
Juliet Thompson - NID
Antony Fitzpatrick - EVP
William Downie - CEO
Mark Bridgewater - OTH
Christina Olsen - EVP
Sharon Johnson - EVP
Who are the major shareholders of Vectura?

Here are the top five shareholders of Vectura based on the size of their shareholding:

INVESCO Asset Management Limited Investment Advisor/Hedge Fund
Percentage owned: 8.33% (50.1m shares)
AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund
Percentage owned: 6.05% (36.4m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 4.94% (29.7m shares)
Aberforth Partners LLP Investment Advisor
Percentage owned: 4.93% (29.7m shares)
Columbia Threadneedle Investments (UK) Investment Advisor/Hedge Fund
Percentage owned: 3.62% (21.8m shares)
Similar to VEC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.